Radiopharmaceutical is a hot space in biotech following recent dealsClarity is one of the only companies left with an advanced copper isotopes programStockhead reached out to Clarity’s executive chairperson, Dr Alan Taylor
“Radiopharmaceutical, in the global sense, is a hot market right now. It’s a very interesting space off the back of the antibody drug conjugate market which has already been hot,” said Clarity’s executive chairperson, Dr Alan Taylor.Taylor adds that there is now an extremely limited number of clinically advanced radiopharmaceutical companies remaining which could provide Big Pharma with a platform entry point to radiopharmaceutical therapeutics.“There’s no one left but us really in this exciting radiopharma space,” he said.
“So Copper-67 is perfect for therapy, and it allows us to dose the patient a lot more on the same day,” said Taylor, adding that the shorter half-life results in shorter duration of radiation exposure to the patient and surrounding healthy tissues.“That’s why it’s so exciting, because we basically own this copper thermal theranostic market,” he said.
Taylor says the next big catalyst will be the results from the SECuRE trial.“When you look at big pharmas, they don’t necessarily love diagnostics but they love therapies. I don’t know of any big pharma that’s just focused on diagnostics.“So, the value for Clarity is on the incredible therapeutic data we’ve got today,” he said.“The market in this space is incredibly intense right now. There is a bunch of radiopharma companies that are being acquired without any real product.“But our job is to focus on developing amazing products and differentiate ourselves from the rest of the market.“We will focus on maintaining those barriers to entry, our strong intellectual property, because at the end of the day, we have to deliver these products to patients.“That’s our primary job, and that’ll be our focus over the next period following the recent cap raise,” said Taylor.
https://unauthorised investment advice/health/radiopharmaceutical-emerges-as-the-hottest-space-in-biotech-heres-what-it-means-for-clarity-pharma/
https://stocks.apple.com/AyHgLZzfHSJWQl7qFEY4f1g
CU6 - Media and Industry News, page-67
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.20 |
Change
0.190(2.71%) |
Mkt cap ! $2.305B | |||
| Open | High | Low | Value | Volume |
| $7.12 | $7.34 | $6.95 | $5.698M | 788.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 16776 | $7.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.27 | 197 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |